RNS Number : 9743S
OptiBiotix Health PLC
02 September 2026

OptiBiotix Health plc
("OptiBiotix" or the "Company" or "the Group")

Holland & Barrett (H&B) launches FORMI™ Weight loss Complex containing SlimBiome®

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces the launch of a new weight management product containing its clinically validated SlimBiome® formulation under Holland & Barrett's ("H&B") new own-brand, FORMI™.

H&B has over 1,600 stores worldwide across 19 countries, including over 700 stores in the United Kingdom. In December 2025 OptiBiotix signed a new 3-year non-exclusive trademark licence agreement (TMLA) granting H&B rights to use SlimBiome® and LeanBiome® marks on new products containing OptiBiotix's patented mineral enriched dietary fibre and prebiotic ingredients. SlimBiome® has now been launched under a newly formed H&B's own-label brand, FORMI™, encompassing active nutrition, weight management, and healthy food products.

The new FORMI WEIGHT LOSS COMPLEX is available online and in H&B stores, sold as a satiety supporting weight loss complex in Raspberry flavoured powdered drink sachets. The product has on-pack health claims of supporting weight management, helping to control blood sugar, and supporting satiety. The product is targeted at consumers seeking non-drug approaches to weight management, including those who are overweight, consumers who do not tolerate GLP-1 treatments, and consumers seeking nutritional support following GLP-1 treatment.

A changing weight management market
The rapid adoption of GLP-1-based medicines has fundamentally changed the weight management market and creating demand for complementary, non-drug approaches. Emerging evidence suggests that weight regain following discontinuation of GLP-1 treatment can be significant, highlighting the potential importance of longer-term approaches to maintaining weight loss. Research from the University of Oxford (BMJ, Jan 2026) has reported that people stopping weight-loss medication can regain weight more rapidly than those ending traditional diet-based programmes. Separately, research published by The Journal of Obesity (2023) highlighted high rates of discontinuation among people prescribed GLP-1 weight-loss medicines and the challenges associated with maintaining weight loss following treatment.

This changing market dynamic has contributed to the emergence of a rapidly growing category of products positioned to support consumers before, during or following GLP-1 treatment. The global GLP-1 support supplements market has been estimated at approximately $1.8 billion in 2025 and is forecast to reach $8.9 billion by 2034, representing a CAGR of approximately 18.5% (MarketIntelo, 2026).

The launch of FORMI™ Weight Loss Complex further strengthens OptiBiotix's relationship with H&B and follows H&B's May 2026 announcement of a weight management partnership with online pharmacy Phlo. The partnership provides H&B customers with access to Phlo's clinical weight management services, including GLP-1 anti-obesity medicines, alongside H&B's existing nutrition, wellness and weight management offering. The combination of clinical weight management services with nutritional and lifestyle products reflects the increasingly holistic approach being adopted within the weight management market.

Stephen O'Hara, CEO of OptiBiotix Health plc said: *"The introduction and rapid adoption of GLP-1 medicines has led to a fundamental shift in the weight management market and created a significant new opportunity for nutritional products that can complement pharmaceutical approaches.*

"SlimBiome®, supported by clinical studies, authorised health claims in major territories and multiple international awards, is increasingly being recognised as a clinically validated, natural approach to appetite, hunger and satiety management. We believe this positions SlimBiome® well both as a non-drug option for consumers seeking support with weight management and as a potential nutritional solution for consumers seeking to maintain their weight following GLP-1 treatment.

"We are particularly pleased to see H&B incorporating SlimBiome® into its new FORMI™ own-brand range. This demonstrates the growing recognition of SlimBiome® by major weight management and health and wellness businesses. We are seeing increasing interest from progressive companies seeking to incorporate SlimBiome® into their own branded products,

purchase finished products developed by OptiBiotix, or use SlimBiome® in flavoured or unflavoured sachets as a range extension.

"The launch of FORMI™ Weight Loss Complex represents an important further step in our relationship with H&B and provides an opportunity for SlimBiome® to participate in the expansion of H&B's own-brand weight management portfolio."

For further information, please contact: OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman
Stephen O'Hara, Chief Executive

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and manage human disease. Since the Group's inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABUGDCRXGDGLB